Atossa Genetics Stock Performance
| ATOS Stock | USD 1.28 0.06 4.92% |
The firm shows a Beta (market volatility) of 1.99, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Atossa Genetics will likely underperform. At this point, Atossa Genetics has a negative expected return of -0.11%. Please make sure to confirm Atossa Genetics' potential upside, as well as the relationship between the rate of daily change and relative strength index , to decide if Atossa Genetics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Atossa Genetics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors. ...more
Last Split Factor 1:12 | Dividend Date 2018-04-20 | Last Split Date 2018-04-20 |
1 | Acquisition by Chen Shu-chih of 50000 shares of Atossa Genetics at 2.9 subject to Rule 16b-3 | 09/04/2024 |
2 | Acquisition by Steinhart Richard I of 50000 shares of Atossa Genetics at 0.93 subject to Rule 16b-3 | 09/05/2024 |
3 | Disposition of 2300000 shares by Quay Steven C of Atossa Genetics at 2.38 subject to Rule 16b-3 | 09/06/2024 |
4 | Availability of the adjusted draft accelerated safeguard plan | 09/16/2024 |
5 | Atos appoints Philippe Salle as new chairman and CEO | 10/15/2024 |
6 | US District Court for the Southern District of New York orders a new trial on compensatory damages in Atos litigation with TriZetto | 10/25/2024 |
7 | Are Medical Stocks Lagging Atossa Genetics This Year | 10/28/2024 |
8 | HC Wainwright Reiterates Buy Rating for Atossa Therapeutics | 11/01/2024 |
9 | Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development | 11/05/2024 |
10 | Atossa Genetics stock target lifted, retains buy on positive study results | 11/13/2024 |
11 | Atossa Therapeutics Announces Five Abstracts Highlighting -Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium | 11/20/2024 |
12 | Atossa Therapeutics to Present Poster on -Endoxifen at AACR Special Conference in Cancer Research | 11/21/2024 |
| Begin Period Cash Flow | 111 K | |
| Free Cash Flow | -21 K |
Atossa |
Atossa Genetics Relative Risk vs. Return Landscape
If you would invest 135.00 in Atossa Genetics on August 27, 2024 and sell it today you would lose (13.00) from holding Atossa Genetics or give up 9.63% of portfolio value over 90 days. Atossa Genetics is currently does not generate positive expected returns and assumes 3.2696% risk (volatility on return distribution) over the 90 days horizon. In different words, 29% of stocks are less volatile than Atossa, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Atossa Genetics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Atossa Genetics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Atossa Genetics, and traders can use it to determine the average amount a Atossa Genetics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0323
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ATOS |
Estimated Market Risk
| 3.27 actual daily | 29 71% of assets are more volatile |
Expected Return
| -0.11 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Atossa Genetics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Atossa Genetics by adding Atossa Genetics to a well-diversified portfolio.
Atossa Genetics Fundamentals Growth
Atossa Stock prices reflect investors' perceptions of the future prospects and financial health of Atossa Genetics, and Atossa Genetics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Atossa Stock performance.
| Return On Equity | -0.31 | ||||
| Return On Asset | -0.2 | ||||
| Current Valuation | 78.71 M | ||||
| Shares Outstanding | 125.8 M | ||||
| Price To Earning | (0.62) X | ||||
| Price To Book | 2.08 X | ||||
| EBITDA | (31.35 M) | ||||
| Net Income | (30.09 M) | ||||
| Cash And Equivalents | 125.54 M | ||||
| Cash Per Share | 0.99 X | ||||
| Total Debt | 5.24 M | ||||
| Current Ratio | 35.19 X | ||||
| Book Value Per Share | 0.59 X | ||||
| Cash Flow From Operations | (20.94 M) | ||||
| Earnings Per Share | (0.21) X | ||||
| Market Capitalization | 153.48 M | ||||
| Total Asset | 96.25 M | ||||
| Retained Earnings | (186.29 M) | ||||
| Working Capital | 112.63 M | ||||
| Current Asset | 4.29 M | ||||
| Current Liabilities | 2.5 M | ||||
About Atossa Genetics Performance
Assessing Atossa Genetics' fundamental ratios provides investors with valuable insights into Atossa Genetics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Atossa Genetics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 23.6 K | 25.4 K | |
| Return On Tangible Assets | (0.31) | (0.33) | |
| Return On Capital Employed | (0.34) | (0.36) | |
| Return On Assets | (0.31) | (0.33) | |
| Return On Equity | (0.33) | (0.35) |
Things to note about Atossa Genetics performance evaluation
Checking the ongoing alerts about Atossa Genetics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Atossa Genetics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Atossa Genetics generated a negative expected return over the last 90 days | |
| Atossa Genetics may become a speculative penny stock | |
| Atossa Genetics has high historical volatility and very poor performance | |
| Net Loss for the year was (30.09 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Atossa Genetics currently holds about 125.54 M in cash with (20.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.99. | |
| Atossa Genetics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Atossa Therapeutics to Present Poster on -Endoxifen at AACR Special Conference in Cancer Research |
- Analyzing Atossa Genetics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Atossa Genetics' stock is overvalued or undervalued compared to its peers.
- Examining Atossa Genetics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Atossa Genetics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Atossa Genetics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Atossa Genetics' stock. These opinions can provide insight into Atossa Genetics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Atossa Stock Analysis
When running Atossa Genetics' price analysis, check to measure Atossa Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atossa Genetics is operating at the current time. Most of Atossa Genetics' value examination focuses on studying past and present price action to predict the probability of Atossa Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atossa Genetics' price. Additionally, you may evaluate how the addition of Atossa Genetics to your portfolios can decrease your overall portfolio volatility.